Jeffrey J. Tolin

Cooley advised Rooam, a contactless payment platform that integrates directly into existing point of sale systems without adding extra hardware, on its agreement to be acquired by American Express (NYSE: AXP), a globally integrated payments company providing customers with access to products, insights and experiences that enrich lives and build business success.

Cooley advised Yardi Systems, a large software corporation with offices worldwide, in connection with WeWork’s emergence from Chapter 11 and completion of WeWork’s global operational and financial restructuring.

Cooley advised Nuvalence, a technology consultancy firm, on its acquisition by EY to accelerate the delivery of platform engineering, product development, and generative artificial intelligence platform-enabled services to organizations across industries and sectors.

Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.

Cooley advised COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, on the close of its $105 million Series A financing.